drugset / Trial / NCT03957954
Stem Cell Therapy for Limbal Stem Cell Deficiency
Phase 1
Active not recruiting
20 enrolled
University of California, Los Angeles
California Institute for Regenerative Medicine (CIRM) · collabNational Eye Institute (NEI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).
Timeline
- Start
- 2020-09-30
- Primary completion
- 2027-02-04
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cLSC | Cell therapy | — | — |